20 results
8-K
EX-99.1
NMRD
Nemaura Medical Inc
14 Aug 23
Nemaura Medical Reports Fiscal First Quarter 2024 Results and Provides Business Update
8:30am
$6.5m as non-dilutive funding in the form of clean debt without any warrants or convertible elements.
Financial Summary:
Research and development (“R&D”) expenses
8-K
EX-99.1
NMRD
Nemaura Medical Inc
13 Nov 23
Nemaura Medical Reports Fiscal Second Quarter 2024 Results and Provides Business Update
4:15pm
of the program in various territories.
Financial Summary:
Research and development (“R&D”) expenses were $491,803 and $257,061 for the three months ended
424B4
gis 8v1548
15 May 23
Prospectus supplement with pricing info
4:31pm
424B8
28nsw
11 Sep 23
Prospectus unintentially filed late
4:41pm
POS AM
fnb3d91l634
3 Aug 23
Prospectus update (post-effective amendment)
4:08pm
- Prev
- 1
- Next